Loading clinical trials...

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy. | Clinical Trials | Clareo Health

COMPLETEDPHASE2

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.

NCT00141414•Pfizer

View on ClinicalTrials.gov

Summary

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria

•Pregnant or considering becoming pregnant.
•Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.

Locations (25)

Pfizer Investigational Site

Little Rock, Arkansas, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Stanford, California, United States

Pfizer Investigational Site

Miami, Florida, United States

Pfizer Investigational Site

Plantation, Florida, United States

Pfizer Investigational Site

Indianapolis, Indiana, United States

Pfizer Investigational Site

Indianapolis, Indiana, United States

Pfizer Investigational Site

Baltimore, Maryland, United States

Pfizer Investigational Site

Baltimore, Maryland, United States

Pfizer Investigational Site

Boston, Massachusetts, United States

Key Dates

Start Date

November 1, 1997

Completion Date

October 1, 2005

Last Updated

January 1, 2007

Enrollment

Estimated participants

Conditions

Epilepsy, Partial

Interventions

Pregabalin

DRUG

Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

NCT01457989

Epilepsy, Partial

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 1, 2007Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions